POLE2

Summary

POLE2 (DNA polymerase epsilon 2, accessory subunit, HGNC:9178) is a protein-coding gene on chromosome 14q21.3, encoding DNA polymerase epsilon subunit 2 (P56282). Accessory component of the DNA polymerase epsilon complex. It is a common-essential gene (DepMap: required in 99.6% of cancer cell lines).

DNA polymerase epsilon, which is involved in DNA repair and replication, is composed of a large catalytic subunit and a small accessory subunit. The protein encoded by this gene represents the small subunit (B). Defects in this gene have been linked to colorectal cancer and to combined immunodeficiency.

Source: NCBI Gene 5427 — RefSeq curated summary.

At a glance

• Gene–disease (curated): combined immunodeficiency (Limited, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 465 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 99.6% of screened cell lines (common-essential)
• MANE Select transcript: NM_002692

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9178
Approved symbol	POLE2
Name	DNA polymerase epsilon 2, accessory subunit
Location	14q21.3
Locus type	gene with protein product
Status	Approved
Aliases	DPE2
Ensembl gene	ENSG00000100479
Ensembl biotype	protein_coding
OMIM	602670
Entrez	5427

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 8 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000216367, ENST00000539565, ENST00000553805, ENST00000553850, ENST00000554377, ENST00000554396, ENST00000554671, ENST00000554851, ENST00000555724, ENST00000556937, ENST00000700174, ENST00000700175, ENST00000700176, ENST00000960548, ENST00000960549

RefSeq mRNA: 5 — MANE Select: NM_002692 NM_001197330, NM_001197331, NM_001348384, NM_001348385, NM_002692

CCDS: CCDS32073, CCDS55914, CCDS55915

Canonical transcript exons

ENST00000216367 — 19 exons

Exon	Start	End
ENSE00000940761	49674350	49674427
ENSE00001507517	49664626	49664674
ENSE00001507518	49665107	49665163
ENSE00002521948	49688136	49688214
ENSE00003484987	49674123	49674216
ENSE00003497125	49666330	49666413
ENSE00003533273	49653990	49654067
ENSE00003608845	49679725	49679800
ENSE00003618568	49655671	49655843
ENSE00003642639	49655005	49655094
ENSE00003646275	49663315	49663387
ENSE00003668663	49669524	49669598
ENSE00003695222	49683593	49683693
ENSE00003979029	49647293	49647360
ENSE00003979034	49643555	49643670
ENSE00003979035	49654155	49654214
ENSE00003979038	49654784	49654838
ENSE00003979039	49650265	49650441
ENSE00003979042	49651269	49651377

Expression profiles

Bgee: expression breadth ubiquitous, 197 present calls, max score 94.31.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.5339 / max 178.9283, expressed in 1345 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
143089	6.8978	1302
143090	0.6362	397

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	94.31	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.94	gold quality
ventricular zone	UBERON:0003053	85.02	gold quality
secondary oocyte	CL:0000655	84.94	gold quality
mucosa of transverse colon	UBERON:0004991	83.36	gold quality
adrenal tissue	UBERON:0018303	82.90	gold quality
rectum	UBERON:0001052	82.27	gold quality
ganglionic eminence	UBERON:0004023	82.00	gold quality
right uterine tube	UBERON:0001302	81.28	gold quality
esophagus mucosa	UBERON:0002469	80.97	gold quality
ectocervix	UBERON:0012249	80.92	gold quality
right ovary	UBERON:0002118	80.50	gold quality
embryo	UBERON:0000922	80.19	gold quality
right lobe of liver	UBERON:0001114	79.37	gold quality
cervix squamous epithelium	UBERON:0006922	79.28	gold quality
bone marrow	UBERON:0002371	79.18	gold quality
left ovary	UBERON:0002119	79.04	gold quality
endocervix	UBERON:0000458	78.80	gold quality
right lobe of thyroid gland	UBERON:0001119	78.74	gold quality
body of uterus	UBERON:0009853	78.64	gold quality
metanephros cortex	UBERON:0010533	78.45	gold quality
oocyte	CL:0000023	78.40	gold quality
small intestine Peyer’s patch	UBERON:0003454	78.40	gold quality
body of pancreas	UBERON:0001150	77.91	gold quality
vagina	UBERON:0000996	77.61	gold quality
transverse colon	UBERON:0001157	77.48	gold quality
lower esophagus mucosa	UBERON:0035834	77.44	gold quality
left lobe of thyroid gland	UBERON:0001120	77.17	gold quality
ovary	UBERON:0000992	77.04	gold quality
bone element	UBERON:0001474	76.94	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.99
E-GEOD-75367	no	128.63
E-MTAB-4850	no	32.47

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F1, E2F4, NFIC, SP1

miRNA regulators (miRDB)

13 targeting POLE2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-4502	99.65	66.99	1021
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-2115-3P	99.31	69.68	2026
HSA-MIR-2054	99.20	68.89	1699
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-361-5P	98.95	70.16	1340
HSA-MIR-6792-5P	98.39	68.16	1330
HSA-MIR-1245B-3P	98.01	68.91	1387
HSA-MIR-3074-3P	97.83	67.26	922
HSA-MIR-4662A-3P	97.02	67.77	941

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.6% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 10)

• The solution structure of the N-terminal domain of human DNA polymerase epsilon subunit B revealed a domain that consists of a left-handed superhelical bundle. (PMID:18676977)
• found that mutations occurred in POLE2 in 5 out of 16 cases of human colon cancer examined. (PMID:20065316)
• Inhibition of DNA polymerases a, delra and e by AFP promoter-driven artificial microRNAs may lead to effective growth arrest of AFP-positive HCC cells,as novel strategy for gene therapy (PMID:25924900)
• Genetic Risk of Trigger Finger: Results of a Genomewide Association Study. (PMID:32740585)
• POLE2 facilitates the malignant phenotypes of glioblastoma through promoting AURKA-mediated stabilization of FOXM1. (PMID:35039475)
• POLE2 knockdown suppresses lymphoma progression via downregulating Wnt/beta-catenin signaling pathway. (PMID:37097331)
• Knockdown of HDAC10 inhibits POLE2-mediated DNA damage repair in NSCLC cells by increasing SP1 acetylation levels. (PMID:37657752)
• Inhibition of ferroptosis by POLE2 in gastric cancer cells involves the activation of NRF2/GPX4 pathway. (PMID:38070189)
• POLE2 Regulates Apoptosis of Oral Squamous Cell Carcinoma Cells through the PI3K/AKT Signaling Pathway. (PMID:38079056)
• The Prognostic Hub Gene POLE2 Promotes BLCA Cell Growth via the PI3K/AKT Signaling Pathway. (PMID:38963027)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pole2	ENSDARG00000100028
mus_musculus	Pole2	ENSMUSG00000020974
rattus_norvegicus	Pole2	ENSRNOG00000004242
drosophila_melanogaster	PolE2	FBGN0035644
caenorhabditis_elegans		WBGENE00017237

Protein

Protein identifiers

DNA polymerase epsilon subunit 2 — P56282 (reviewed: P56282)

Alternative names: DNA polymerase II subunit 2, DNA polymerase epsilon subunit B

All UniProt accessions (6): P56282, A0A8V8TPE4, A0A8V8TPU0, A0A8V8TQQ0, A0A8V8TR10, U3KQ22

UniProt curated annotations — full annotation on UniProt →

Function. Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication.

Subunit / interactions. Component of the DNA polymerase epsilon complex consisting of four subunits: the catalytic subunit POLE and the accessory subunits POLE2, POLE3 and POLE4.

Subcellular location. Nucleus.

Miscellaneous. In eukaryotes there are five DNA polymerases: alpha, beta, gamma, delta, and epsilon which are responsible for different reactions of DNA synthesis.

Similarity. Belongs to the DNA polymerase epsilon subunit B family.

Isoforms (3)

UniProt ID	Names	Canonical?
P56282-1	1	yes
P56282-2	2
P56282-3	3

RefSeq proteins (5): NP_001184259, NP_001184260, NP_001335313, NP_001335314, NP_002683* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007185	DNA_pol_a/d/e_bsu	Domain
IPR016266	POLE2	Family
IPR024639	DNA_pol_e_bsu_N	Domain

Pfam: PF04042, PF12213

Enzyme classification (BRENDA):

• EC 2.7.7.7 — DNA-directed DNA polymerase (BRENDA: 139 organisms, 372 substrates, 325 inhibitors, 281 Km, 239 kcat entries)

Substrate kinetics (BRENDA)

52 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
DATP	0.0003–3.2	52
DCTP	0.0001–2.5	46
DTTP	0.0003–47.4	46
DGTP	0.0002–2.5	29
DEOXYNUCLEOSIDE TRIPHOSPHATE	0.0012–0.64	12
DNAN	—	7
7-DEAZA-2’-DEOXYADENOSINE 5’-TRIPHOSPHATE	0.0011–0.344	5
N1-METHYL-2’-DEOXYADENOSINE 5’-TRIPHOSPHATE	0.223–0.403	5
2-AMINOPURINE-2’-DEOXY-D-RIBOSE 5’-TRIPHOSPHATE	0.006–0.0144	2
2-THIO-DCTP	0.067–0.98	2
5-METHYL-DCTP	0.013–1.22	2
DAMP:DG	1.153–1.42	2
DCMP:DG	—	2
DGMP:DG	0.263–0.3511	2
DTMP:DG	1.26–1.43	2

UniProt features (55 total): strand 22, helix 19, turn 6, sequence variant 3, splice variant 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
5VBN	X-RAY DIFFRACTION	2.35
7PLO	ELECTRON MICROSCOPY	2.8
7PFO	ELECTRON MICROSCOPY	3.2
2V6Z	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P56282-F1	93.16	0.81

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-110314	Recognition of DNA damage by PCNA-containing replication complex
R-HSA-5651801	PCNA-Dependent Long Patch Base Excision Repair
R-HSA-5656169	Termination of translesion DNA synthesis
R-HSA-5685942	HDR through Homologous Recombination (HRR)
R-HSA-5696397	Gap-filling DNA repair synthesis and ligation in GG-NER
R-HSA-5696400	Dual Incision in GG-NER
R-HSA-6782135	Dual incision in TC-NER
R-HSA-6782210	Gap-filling DNA repair synthesis and ligation in TC-NER
R-HSA-68952	DNA replication initiation
R-HSA-68962	Activation of the pre-replicative complex

MSigDB gene sets: 298 (showing top): E2F_Q4, REACTOME_DNA_REPLICATION, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, E2F_Q4_01, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, E2F4DP1_01, PAL_PRMT5_TARGETS_UP, FISCHER_G1_S_CELL_CYCLE, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GENTILE_RESPONSE_CLUSTER_D3, GOBP_DNA_DAMAGE_TOLERANCE, KAUFFMANN_DNA_REPAIR_GENES, PUJANA_CHEK2_PCC_NETWORK, WEI_MYCN_TARGETS_WITH_E_BOX

GO Biological Process (5): DNA replication (GO:0006260), DNA-templated DNA replication (GO:0006261), DNA repair (GO:0006281), error-prone translesion synthesis (GO:0042276), DNA metabolic process (GO:0006259)

GO Molecular Function (3): DNA binding (GO:0003677), DNA-directed DNA polymerase activity (GO:0003887), protein binding (GO:0005515)

GO Cellular Component (6): nucleoplasm (GO:0005654), epsilon DNA polymerase complex (GO:0008622), nuclear body (GO:0016604), nucleus (GO:0005634), chromosome (GO:0005694), nuclear lumen (GO:0031981)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Global Genome Nucleotide Excision Repair (GG-NER)	2
Transcription-Coupled Nucleotide Excision Repair (TC-NER)	2
DNA Damage Bypass	1
Resolution of AP sites via the multiple-nucleotide patch replacement pathway	1
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template	1
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	1
Synthesis of DNA	1
DNA Replication Pre-Initiation	1
G1/S Transition	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA metabolic process	2
intracellular membraneless organelle	2
DNA biosynthetic process	1
DNA replication	1
DNA damage response	1
translesion synthesis	1
nucleic acid metabolic process	1
nucleic acid binding	1
DNA polymerase activity	1
binding	1
nuclear lumen	1
cellular anatomical structure	1
nuclear chromosome	1
DNA polymerase complex	1
nuclear protein-containing complex	1
nucleoplasm	1
intracellular membrane-bounded organelle	1
nucleus	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

1672 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
POLE2	POLE3	Q9NRF9	994
POLE2	POLE	Q07864	989
POLE2	POLE4	Q9NR33	988
POLE2	POLA1	P09884	848
POLE2	POLA2	Q14181	838
POLE2	POLD2	P49005	828
POLE2	POLD1	P28340	819
POLE2	MCM4	P33991	757
POLE2	CDC45	O75419	750
POLE2	MCM10	Q7L590	743
POLE2	RFC4	P35249	716
POLE2	RFC3	P40938	679
POLE2	GINS1	Q14691	666
POLE2	PRIM1	P49642	665
POLE2	PRIM2	P49643	649

IntAct

98 interactions, top by confidence:

A	B	Type	Score
POLE2	POLE	psi-mi:“MI:0915”(physical association)	0.860
POLE	POLE2	psi-mi:“MI:0915”(physical association)	0.860
POLE2	POLE	psi-mi:“MI:0914”(association)	0.860
TRIM27	POLE2	psi-mi:“MI:0915”(physical association)	0.780
POLE2	TRIM27	psi-mi:“MI:0915”(physical association)	0.780
MAPRE1	POLE2	psi-mi:“MI:0915”(physical association)	0.720
POLE2	MAPRE1	psi-mi:“MI:0915”(physical association)	0.720
POLE3	POLE2	psi-mi:“MI:0914”(association)	0.690
KLK5	DENND11	psi-mi:“MI:0914”(association)	0.640
ARL4C	RGS12	psi-mi:“MI:0914”(association)	0.640
DNAJC7	PLD2	psi-mi:“MI:0914”(association)	0.640
LRRC46	TFPT	psi-mi:“MI:0914”(association)	0.640
POLE2	POLE4	psi-mi:“MI:0914”(association)	0.640
AGFG1	POLE2	psi-mi:“MI:0915”(physical association)	0.560
POLE2	REL	psi-mi:“MI:0915”(physical association)	0.560
POLE2	TBX15	psi-mi:“MI:0915”(physical association)	0.560
POLE2	HEL-S-30	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (109): POLE2 (Two-hybrid), POLE2 (Two-hybrid), REL (Two-hybrid), TRIM27 (Two-hybrid), TBX15 (Two-hybrid), MAPRE1 (Two-hybrid), POLE2 (Affinity Capture-RNA), POLE2 (Affinity Capture-MS), POLE2 (Affinity Capture-MS), POLE2 (Affinity Capture-MS), POLE2 (Affinity Capture-MS), POLE2 (Affinity Capture-MS), PEX19 (Co-fractionation), POLE2 (Co-fractionation), POLE2 (Affinity Capture-MS)

ESM2 similar proteins: A2VDL8, A7YWS7, O35142, O54956, O55029, O70133, O88544, O94973, O95782, P17426, P17427, P18484, P35605, P35606, P38024, P48444, P53619, P56282, Q01405, Q05AS9, Q08211, Q0VCK5, Q15436, Q15437, Q28141, Q3SZA0, Q3SZN2, Q41141, Q4R4I8, Q5E9U9, Q5F418, Q5R5G2, Q5R664, Q5R874, Q5R9P3, Q5RA77, Q5XJY5, Q5ZK03, Q5ZKQ6, Q5ZL57

Diamond homologs: A7YWS7, O54956, O94263, P0CN24, P0CN25, P56282, Q19196, Q500V9, Q54Y85, Q5ZKQ6, Q9VRQ7, P24482, Q6BQR8, Q6FSK8, Q758V1, Q6CPH8, Q6C030

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
POLE2	“form complex”	“DNA polymerase epsilon”	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

465 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	267
Likely benign	150
Benign	24

Top pathogenic / likely-pathogenic (0)

SpliceAI

2624 predictions. Top by Δscore:

Variant	Effect	Δscore
14:49650263:A:AC	donor_gain	1.0000
14:49650264:C:CC	donor_gain	1.0000
14:49650264:CAGG:C	donor_gain	1.0000
14:49650264:CAGGG:C	donor_gain	1.0000
14:49650438:CAAA:C	acceptor_gain	1.0000
14:49650442:C:CC	acceptor_gain	1.0000
14:49651263:ACTT:A	donor_loss	1.0000
14:49651265:TTACG:T	donor_loss	1.0000
14:49651267:A:AC	donor_gain	1.0000
14:49651267:ACG:A	donor_loss	1.0000
14:49651268:C:CC	donor_gain	1.0000
14:49651268:CG:C	donor_gain	1.0000
14:49651268:CGT:C	donor_gain	1.0000
14:49651268:CGTG:C	donor_gain	1.0000
14:49651268:CGTGA:C	donor_gain	1.0000
14:49651375:ATT:A	acceptor_gain	1.0000
14:49651376:TT:T	acceptor_gain	1.0000
14:49651378:C:CC	acceptor_gain	1.0000
14:49651383:A:AC	acceptor_gain	1.0000
14:49654192:C:CT	acceptor_gain	1.0000
14:49654210:GACTA:G	acceptor_gain	1.0000
14:49654212:CTA:C	acceptor_gain	1.0000
14:49654213:TA:T	acceptor_gain	1.0000
14:49654215:C:CC	acceptor_gain	1.0000
14:49655001:ATACC:A	donor_loss	1.0000
14:49655002:TACCT:T	donor_loss	1.0000
14:49655003:AC:A	donor_loss	1.0000
14:49655004:C:CG	donor_loss	1.0000
14:49655091:TAAC:T	acceptor_gain	1.0000
14:49655092:AACC:A	acceptor_loss	1.0000

AlphaMissense

3471 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:49651342:C:G	R416P	0.999
14:49664626:C:G	G228R	0.999
14:49666352:C:T	G185E	0.999
14:49653998:A:C	N401K	0.998
14:49653998:A:T	N401K	0.998
14:49664637:A:T	V224D	0.998
14:49666353:C:G	G185R	0.998
14:49666353:C:T	G185R	0.998
14:49665150:A:G	L197P	0.997
14:49647331:G:C	F509L	0.996
14:49647331:G:T	F509L	0.996
14:49647333:A:G	F509L	0.996
14:49650318:C:G	D482H	0.996
14:49650326:A:T	V479D	0.996
14:49663342:G:C	P243R	0.996
14:49663348:C:T	G241E	0.996
14:49663366:A:G	F235S	0.996
14:49663387:C:T	G228D	0.996
14:49665129:A:T	V204D	0.996
14:49666358:A:T	V183D	0.996
14:49669575:A:C	F147L	0.996
14:49669575:A:T	F147L	0.996
14:49669577:A:G	F147L	0.996
14:49674142:C:G	R133P	0.996
14:49650268:G:C	N498K	0.995
14:49650268:G:T	N498K	0.995
14:49655055:C:A	G323V	0.995
14:49655055:C:T	G323D	0.995
14:49663342:G:T	P243Q	0.995
14:49665150:A:C	L197R	0.995

dbSNP variants (sampled 300 via entrez): RS1000072457 (14:49648352 T>A,C), RS1000082441 (14:49667476 G>A), RS1000173169 (14:49677546 C>G,T), RS1000364439 (14:49655563 T>A), RS1000414145 (14:49680471 T>C), RS1000429555 (14:49670158 A>C), RS1000471778 (14:49662223 C>T), RS1000573797 (14:49648880 A>G), RS1000608129 (14:49669965 C>T), RS1000692428 (14:49660943 G>A,T), RS1001090385 (14:49683800 C>G), RS1001115242 (14:49680819 G>C), RS1001244493 (14:49675192 C>G), RS1001278723 (14:49677418 G>A,T), RS1001297420 (14:49680448 G>C)

Disease associations

OMIM: gene MIM:602670 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
combined immunodeficiency	Limited	Autosomal recessive

Mondo (1): combined immunodeficiency (MONDO:0015131)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST011318_2	Trigger finger	1.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010822	stenosing tenosynovitis

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2363042 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

93 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases expression, increases methylation	4
(+)-JQ1 compound	decreases expression	3
Tretinoin	decreases expression	3
Cyclosporine	decreases expression	3
sodium arsenite	decreases expression, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Estradiol	increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Cadmium Chloride	decreases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
afuresertib	decreases expression	1
dicrotophos	decreases expression	1
lasiocarpine	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
2,2’-methylenebis(4-methyl-6-tert-butylphenol)	affects expression, affects response to substance	1
2-methyl-4-isothiazolin-3-one	decreases expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	increases expression, affects cotreatment	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	decreases expression, affects cotreatment	1
phenethyl isothiocyanate	decreases expression	1
2,3-dimethoxy-1,4-naphthoquinone	increases expression	1

Clinical trials (associated diseases)

4 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02737384	PHASE2	TERMINATED	Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)
NCT02915406	Not specified	NO_LONGER_AVAILABLE	cliniMACs HUD for T Cell Depletion
NCT04902807	Not specified	RECRUITING	Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
NCT06659588	Not specified	RECRUITING	Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency